We are proud to announce that MedMira (whose majority shareholder OnSite-Lab is a Redalpine Capital II portfolio company) has received approval from the U.S. Food and Drug Administration for the latest generation of their rapid HIV test. The test adds new capabilities in testing fingerstick and venipuncture whole blood specimens, extending the product line beyond laboratories and hospitals into point-of-care settings.
Today more than 1.2 million people are living with HIV, and as many as 168,000 remain unaware of their infection. MedMira has been employing its patented Rapid Vertical Flow Technology to deliver FDA-grade results in 3 minutes. "This product is all about creating a rapid HIV testing solution that gives healthcare providers and their patients choices that make testing possible in any setting,” said Hermes Chan, CEO, MedMira Inc.
MedMira’s technology allows users to obtain instant results, therefore enabling counselling and, if needed, initial treatment, to be delivered in a single patient visit. As healthcare providers look for cost-efficient ways to integrate routine HIV testing in their practices and programs, a tool like MedMira’s new rapid HIV test offers the speed and quality which will be critical to success.
For the full press release and more information, please visit medmira.com.